Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Flat Capital AB (publ) in connection with its listing on Nasdaq First North Growth Market

October 20, 2021 Capital Markets and Public M&A

Vinge has advised Flat Capital AB (publ) (“Flat Capital” or the “Company”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 September 2021 and the first day of trading on Nasdaq First North Growth Market was 20 October 2021.

Flat Capital is an investment company founded by Nina and Sebastian Siemiatkowski that focuses on companies with prominent entrepreneurs in leading positions. The company aims to contribute long-term capital to entrepreneur-led companies that may otherwise be dependent on investors with shorter time horizons. The largest investments are Klarna Holding AB, Budbee AB and True Software Scandinavia AB (Truecaller).


Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Anna Grigorian and Anna Svensson.

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025